Immuneering Corporation
IPOImmuneering | Deep Cyclic Inhibitors for MAPK-Driven Cancers
Public · Cambridge, United States · Founded 2008 · $25.0M raised
- Headquarters
- Cambridge, Massachusetts
- Employees
- 11–50
- Founded
- 2008
- Business Model
- B2B
- Website
- immuneering.com
- Total Funding
- $25.0M
- Last Round
- $25.0M Private EquityAug 2025
- Rounds
- 1
- Type
- Public
About
Clinical-stage oncology company developing Deep Cyclic Inhibitors — a new class of cancer therapies targeting MAPK-driven cancers.
Summary
Immuneering Corporation is a Biotech company based in Cambridge, United States, founded in 2008. It has raised $25.0M in total across 1 round, most recently a $25.0M Private Equity round in Aug 2025. Investors include Leerink Partners, Oppenheimer Holdings and Sanofi Ventures.
Tech & App Stack
2 technologies & apps tracked
Create a free account to track companies, build lists, and unlock premium data like the full tech & app stack.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Sep 2025
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...